Skip to main
IMDX
IMDX logo

Oncocyte Corp (IMDX) Stock Forecast & Price Target

Oncocyte Corp (IMDX) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Insight Molecular Diagnostics Inc. has a promising outlook due to the potential expansion of its addressable market by 10-20% through the introduction of new testing indications for immunosuppression and rejection monitoring, currently under evaluation with its GraftAssure RUO technology. The company's focus on advancing its portfolio of diagnostic tests for organ transplant monitoring and cancer positions it for strong long-term revenue growth. Key drivers of potential upside include upcoming clinical data releases, favorable updates to NCCN guidelines, and faster-than-anticipated revenue growth.

Bears say

Insight Molecular Diagnostics Inc. is experiencing a significant decline in gross margin, dropping to 53.5% from 67.6% in the previous quarter, reflecting challenges in maintaining profitability despite being above internal estimates. Furthermore, while cash burn has decreased sequentially, the company's anticipated earnings per share (EPS) for 2025 have been revised downward to ($1.11), indicating ongoing financial struggles. The risks associated with this outlook include slow physician adoption of new diagnostic tests, potential delays in insurer coverage and reimbursement, and the possibility of dilutive equity offerings, all of which may hinder the company's growth prospects and financial stability.

Oncocyte Corp (IMDX) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Oncocyte Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Oncocyte Corp (IMDX) Forecast

Analysts have given Oncocyte Corp (IMDX) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Oncocyte Corp (IMDX) has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Oncocyte Corp (IMDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.